(Q44896050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Group B meningococcal vaccine: recommendations for UK use (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

main subject

meningococcal vaccine

1 reference

Andrew Riordan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

21 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

9923

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

1103-1104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study.

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

The price of prevention: what now for immunisation against meningococcus B?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

Vaccine economics: what price human life?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960226-9

7 January 2021

10.1016/S0140-6736(14)60226-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24661533%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference